series-c-plus
Stage
1994
Founded
1
Investors
About
Agenus develops cancer immunotherapies, including a clinical pipeline of proprietary cancer vaccines and monoclonal antibodies that target the immune system for cancer therapy. The company has collaborations on checkpoint modulators with partners such as Merck and Incyte and is publicly listed on NASDAQ.
Explore Agenus's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.